Toinv - I agree with your opinion that it would be 2013 all over again. One big differences we have in this BETonMACE trial is the secondary end points of kidney function and Alzheimer's. We could end up missing the primary end point of 30% RRR which would have a negative effect on the share price initially but then have some good or great experiences for the secondary end points which may turn the share price around. Admittedly it would be very hard on the share price initially as this would be the 3rd time in a row that RVX would have missed a primary end point. The previous 2 misses likely have something to do with the excitement or lack there of around our share price at this time.

dyodd

tada